Zydus Life Science Intrinsic Value
Zydus Life Science (ZYDUSLIFE) median intrinsic value is ₹2171.60 from 9 valuation models (range ₹326–₹2715), vs current price ₹1085.80 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Also explore ZYDUSLIFE share price data to track price trends across different timeframes.
ZYDUSLIFE Valuation Methods Summary — DCF, Graham Number & P/E
Zydus Life Science intrinsic value across 9 models vs current price ₹1085.80 — upside/downside and value range per method. Browse ZYDUSLIFE financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1113.20 | ₹890.56 - ₹1335.84 | +2.5% | EPS: ₹50.60, Sector P/E: 22x |
| Book Value Method | asset | ₹2714.50 | ₹2443.05 - ₹2985.95 | +150.0% | Book Value/Share: ₹2684.26, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2171.60 | ₹1954.44 - ₹2388.76 | +100.0% | Revenue/Share: ₹2997.62, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2171.60 | ₹1954.44 - ₹2388.76 | +100.0% | EBITDA: ₹8556.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2714.50 | ₹2171.60 - ₹3257.40 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹325.74 | ₹293.17 - ₹358.31 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹781.77 | ₹703.59 - ₹859.95 | -28.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2171.60 | ₹1954.44 - ₹2388.76 | +100.0% | ROE: 19.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1748.15 | ₹1573.34 - ₹1922.97 | +61.0% | EPS: ₹50.60, BVPS: ₹2684.26 |
ZYDUSLIFE Intrinsic Value vs Market Price — All Valuation Models
Zydus Life Science fair value range ₹326–₹2715 vs current market price ₹1085.80 across 9 valuation models. For current market price and key ratios, visit Zydus Life Science share price today.
ZYDUSLIFE Intrinsic Value Analysis — Undervalued or Overvalued?
Zydus Life Science median intrinsic value ₹2171.60, current price ₹1085.80 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of ZYDUSLIFE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Zydus Life Science (ZYDUSLIFE) is ₹2171.60 (median value). With the current market price of ₹1085.80, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹325.74 to ₹2714.50, indicating ₹325.74 - ₹2714.50.
Is ZYDUSLIFE undervalued or overvalued?
Based on our multi-method analysis, Zydus Life Science (ZYDUSLIFE) appears to be trading below calculated value by approximately 100.0%.
ZYDUSLIFE Financial Health — Key Ratios vs Industry Benchmarks
Zydus Life Science financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.80 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 19.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.58x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ZYDUSLIFE Cash Flow Quality — Operating & Free Cash Flow
Zydus Life Science operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹6,777 Cr | ₹2,589 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹3,228 Cr | ₹2,482 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹2,689 Cr | ₹2,689 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹2,104 Cr | ₹2,104 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹3,293 Cr | ₹2,876 Cr | Positive Free Cash Flow | 8/10 |